A 2026 industry survey finds mounting pressure from PBMs, federal pricing reforms, and compliance scrutiny, as manufacturers ...
In the second part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, suggests that 2026 pharma M&A may fall short of last year’s $220 billion ...
In today’s Pharma Pulse, the Senate tackles the regulatory red tape driving physician burnout, while Edwards Lifesciences ends its anti-copycat policy to settle European Commission antitrust concerns.
The approaching patent cliff—projected to expose as much as $300 billion in annual drug sales to loss of exclusivity by 2032—is expected to keep pharmaceutical M&A activity active in 2026, but not ...
In today’s Pharma Pulse, Eli Lilly amasses a record-breaking stockpile for its oral GLP-1, while new research reveals a 66% reduction in endometrial cancer risk for certain patients.
The Inflation Reduction Act (IRA) promised big changes for Medicare Part D beneficiaries. Beginning in 2026, patients’ annual out-of-pocket (OOP) costs for Part D drugs are capped at $2,100, and the ...
PC: Tecsys’ new survey shows that only 20% of healthcare leaders report having real-time visibility across pharmacy inventory ...
According to Reuters, some of the pharma companies that were not on the receiving end of President Trump’s May executive order (EO) 2 are interested in pursuing separate agreements in order to avoid ...
By unifying data, workflows, and decision-making across partners, AI orchestration is enabling healthcare supply chains to ...
Cell and gene therapies (CGTs) represent one of the most profound breakthroughs in modern medicine, offering the possibility ...
In reality, program design covers everything from offer amount and caps to eligibility rules and channel mix, yet many ...
1. Meijer Announces New Affordable Access to GLP-1 Medications. Meijer. February 10, 2026. Accessed February 11, 2026.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results